Trial Profile
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Therapeutic Hepatitis B Vaccine (Mimogen-based) in Treating Chronic Hepatitis B Patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Hepatitis B vaccine (Primary) ; Adefovir dipivoxil
- Indications Hepatitis B
- Focus Pharmacodynamics
- Sponsors Chongqing Jiachen Biotechnology
- 15 Aug 2021 Primary endpoint has been met. (Percentage of Participants With HBeAg Seroconversion at Endpoint .) as per Results published in the Hepatology
- 15 Aug 2021 percentage of patients with HBeAg seroconversion was amended to the protocol as the primary outcome
- 15 Aug 2021 Results assessing Efficacy and Safety of a Nanoparticle Therapeutic Vaccine in Patients with Chronic Hepatitis B published in the Hepatology